NEW YORK, NY - (ACCESSWIRE - November 11, 2013) - TG Therapeutics, Inc. (TGTX) will host a live webcast to discuss the results of the third quarter 2013, to be held Tuesday, November 12, 2013 at 8:30 a.m. Eastern Time. Michael Weiss, Executive Chairman and Interim Chief Executive Officer, will be the main presenter for this event.
This event will be broadcast live online at http://www.investorcalendar.com/IC/CEPage.asp?ID=171880.
If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=171880 or http://www.investorcalendar.com/, as well as via the TG Therapeutics web site (http://www.tgtherapeutics.com/).
About TG Therapeutics, Inc.
TG Therapeutics, Inc. is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two advanced therapies targeting hematological malignancies. TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, currently in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. TG Therapeutics is also developing TGR-1202, a highly specific, orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐cell lymphocytes. TG Therapeutics is headquartered in New York City.
SOURCE: ACCESSWIRE